(ABBV) AbbVie - Ratings and Ratios
Biologics, Immunology, Oncology, Neuroscience, Ophthalmology
ABBV EPS (Earnings per Share)
ABBV Revenue
Description: ABBV AbbVie September 24, 2025
AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical firm that develops, manufactures, and commercializes a broad portfolio of medicines across immunology, oncology, neuroscience, eye care, virology, and specialty therapeutics.
Its flagship products include Humira (autoimmune and intestinal diseases), Skyrizi and Rinvoq (psoriasis and inflammatory disorders), Imbruvica and Venclexta (hematologic cancers), Elahere (solid-tumor oncology), and a suite of neuroscience and ophthalmology drugs such as Vraylar, Duopa, Ubrelvy, Qulipta, Ozurdex, and Restasis. The company also markets cosmetic injectables, regenerative-medicine solutions, and gastrointestinal agents like Mavyret, Creon, and Linzess.
In FY 2023 AbbVie generated approximately $58 billion in revenue, with Humira still contributing roughly $2.5 billion despite a 10 % year-over-year decline driven by biosimilar competition. R&D spending was about $5.5 billion, reflecting a continued focus on expanding its oncology pipeline (e.g., Venclexta-based combos) and next-generation immunology candidates. The firm’s operating margin remained above 30 %, a level that is high for the biotech sector.
Key drivers of AbbVie’s outlook include the aging U.S. and global populations that raise demand for chronic-disease biologics, the accelerating rollout of biosimilars that pressure legacy product pricing, and the broader biotech industry’s shift toward gene-editing and cell-therapy platforms, which could reshape competitive dynamics over the next 5-10 years.
For a deeper, data-rich assessment of how these trends may affect AbbVie’s valuation, you may find it worthwhile to explore the analysis on ValueRay.
ABBV Stock Overview
| Market Cap in USD | 403,217m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-01-02 |
ABBV Stock Ratings
| Growth Rating | 86.1% |
| Fundamental | 55.6% |
| Dividend Rating | 70.9% |
| Return 12m vs S&P 500 | 5.41% |
| Analyst Rating | 4.0 of 5 |
ABBV Dividends
| Dividend Yield 12m | 2.88% |
| Yield on Cost 5y | 9.50% |
| Annual Growth 5y | 7.06% |
| Payout Consistency | 100.0% |
| Payout Ratio | 62.0% |
ABBV Growth Ratios
| Growth Correlation 3m | 94.8% |
| Growth Correlation 12m | 68% |
| Growth Correlation 5y | 94.5% |
| CAGR 5y | 20.11% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.97 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.80 |
| Sharpe Ratio 12m | 0.27 |
| Alpha | 14.06 |
| Beta | 0.507 |
| Volatility | 19.65% |
| Current Volume | 3529k |
| Average Volume 20d | 5413k |
| Stop Loss | 221.1 (-3%) |
| Signal | 0.73 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (3.77b TTM) > 0 and > 6% of Revenue (6% = 3.50b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 0.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -18.01% (prev -14.73%; Δ -3.29pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 19.28b > Net Income 3.77b (YES >=105%, WARN >=100%) |
| Net Debt (64.01b) to EBITDA (14.16b) ratio: 4.52 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.77b) change vs 12m ago 0.06% (target <= -2.0% for YES) |
| Gross Margin 74.26% (prev 62.75%; Δ 11.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.79% (prev 38.75%; Δ 3.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.06 (EBITDA TTM 14.16b / Interest Expense TTM 2.86b) >= 6 (WARN >= 3) |
Altman Z'' -0.59
| (A) -0.08 = (Total Current Assets 29.26b - Total Current Liabilities 39.77b) / Total Assets 137.18b |
| (B) -0.08 = Retained Earnings (Balance) -11.50b / Total Assets 137.18b |
| (C) 0.04 = EBIT TTM 5.89b / Avg Total Assets 139.56b |
| (D) -0.09 = Book Value of Equity -13.02b / Total Liabilities 137.32b |
| Total Rating: -0.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 55.60
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 3.90% = 1.95 |
| 3. FCF Margin 31.27% = 7.50 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 4.52 = -2.50 |
| 6. ROIC - WACC (= -1.87)% = -2.33 |
| 7. RoE 142.3% = 2.50 |
| 8. Rev. Trend 16.08% = 1.21 |
| 9. EPS Trend -54.47% = -2.72 |
What is the price of ABBV shares?
Over the past week, the price has changed by -1.75%, over one month by +4.09%, over three months by +21.81% and over the past year by +24.40%.
Is AbbVie a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABBV is around 252.40 USD . This means that ABBV is currently undervalued and has a potential upside of +10.71% (Margin of Safety).
Is ABBV a buy, sell or hold?
- Strong Buy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABBV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 237.5 | 4.2% |
| Analysts Target Price | 237.5 | 4.2% |
| ValueRay Target Price | 277.1 | 21.6% |
ABBV Fundamental Data Overview October 25, 2025
P/E Trailing = 108.6905
P/E Forward = 16.835
P/S = 6.9129
P/B = 50.4573
P/EG = 0.4252
Beta = 0.507
Revenue TTM = 58.33b USD
EBIT TTM = 5.89b USD
EBITDA TTM = 14.16b USD
Long Term Debt = 62.96b USD (from longTermDebt, last quarter)
Short Term Debt = 7.52b USD (from shortTermDebt, last quarter)
Debt = 70.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 64.01b USD (from netDebt column, last quarter)
Enterprise Value = 467.23b USD (403.22b + Debt 70.48b - CCE 6.47b)
Interest Coverage Ratio = 2.06 (Ebit TTM 5.89b / Interest Expense TTM 2.86b)
FCF Yield = 3.90% (FCF TTM 18.24b / Enterprise Value 467.23b)
FCF Margin = 31.27% (FCF TTM 18.24b / Revenue TTM 58.33b)
Net Margin = 6.46% (Net Income TTM 3.77b / Revenue TTM 58.33b)
Gross Margin = 74.26% ((Revenue TTM 58.33b - Cost of Revenue TTM 15.01b) / Revenue TTM)
Gross Margin QoQ = 84.42% (prev 70.01%)
Tobins Q-Ratio = 3.41 (Enterprise Value 467.23b / Total Assets 137.18b)
Interest Expense / Debt = 1.05% (Interest Expense 740.0m / Debt 70.48b)
Taxrate = 39.45% (613.0m / 1.55b)
NOPAT = 3.57b (EBIT 5.89b * (1 - 39.45%))
Current Ratio = 0.74 (Total Current Assets 29.26b / Total Current Liabilities 39.77b)
Debt / Equity = -385.1 (out of range, set to none) (Debt 70.48b / totalStockholderEquity, last quarter -183.0m)
Debt / EBITDA = 4.52 (Net Debt 64.01b / EBITDA 14.16b)
Debt / FCF = 3.51 (Net Debt 64.01b / FCF TTM 18.24b)
Total Stockholder Equity = 2.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.75% (Net Income 3.77b / Total Assets 137.18b)
RoE = 142.3% (Net Income TTM 3.77b / Total Stockholder Equity 2.65b)
RoCE = 8.98% (EBIT 5.89b / Capital Employed (Equity 2.65b + L.T.Debt 62.96b))
RoIC = 4.93% (NOPAT 3.57b / Invested Capital 72.30b)
WACC = 6.80% (E(403.22b)/V(473.70b) * Re(7.88%) + D(70.48b)/V(473.70b) * Rd(1.05%) * (1-Tc(0.39)))
Discount Rate = 7.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.00% ; FCFE base≈18.06b ; Y1≈17.70b ; Y5≈18.06b
Fair Price DCF = 181.5 (DCF Value 320.69b / Shares Outstanding 1.77b; 5y FCF grow -2.90% → 3.0% )
EPS Correlation: -54.47 | EPS CAGR: -7.32% | SUE: 2.23 | # QB: 6
Revenue Correlation: 16.08 | Revenue CAGR: 1.48% | SUE: 0.84 | # QB: 0
Additional Sources for ABBV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle